{"id":"guideline-directed-statin-therapy","safety":{"commonSideEffects":[{"rate":"1-3%","effect":"Muscle pain or myalgia"},{"rate":"1-3%","effect":"Elevated liver enzymes"},{"rate":"<0.1%","effect":"Myopathy or rhabdomyolysis"},{"rate":"0.1-0.3%","effect":"New-onset diabetes"},{"rate":"1-2%","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Statins competitively inhibit the enzyme HMG-CoA reductase, which catalyzes an early rate-limiting step in cholesterol biosynthesis. This leads to decreased intracellular cholesterol, upregulation of LDL receptors on hepatocytes, and increased clearance of LDL cholesterol from circulation. Guideline-directed statin therapy refers to evidence-based dosing and intensity recommendations for statin use based on cardiovascular risk stratification.","oneSentence":"Statins inhibit HMG-CoA reductase to reduce cholesterol synthesis and lower LDL cholesterol levels in the blood.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:47:24.742Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Primary prevention of atherosclerotic cardiovascular disease in high-risk patients"},{"name":"Secondary prevention of cardiovascular events in patients with established coronary artery disease or other atherosclerotic disease"},{"name":"Hyperlipidemia and dyslipidemia management"}]},"trialDetails":[{"nctId":"NCT06676280","phase":"PHASE4","title":"ASpirin Use and stAtin Strategy for Primary Prevention in Severe Coronary Calcium Score on Computed Tomography","status":"RECRUITING","sponsor":"Jung-min Ahn","startDate":"2025-07-24","conditions":"Cardiovascular Diseases","enrollment":5000},{"nctId":"NCT05831085","phase":"NA","title":"Diabetes-Centered Evaluation of Revascularization Strategy of Functional and Imaging-CombiNEd State-of-the-Art Percutaneous Coronary Intervention or Coronary-Artery Bypass Grafting in Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease","status":"RECRUITING","sponsor":"Duk-Woo Park, MD","startDate":"2024-06-14","conditions":"Coronary Artery Stenosis","enrollment":1500},{"nctId":"NCT06855537","phase":"PHASE4","title":"Effectiveness of Interventional Therapy for Non-Flow-Limiting Vulnerable Plaques","status":"RECRUITING","sponsor":"Beijing Anzhen Hospital","startDate":"2025-11-03","conditions":"Coronary Arterial Disease (CAD), Vulnerable Coronary Plaques, Thin-cap fIbroatheroma","enrollment":2190},{"nctId":"NCT06791031","phase":"NA","title":"PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in Acute Coronary Syndromes (REPRESS)","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2026-01","conditions":"Coronary Artery Disease","enrollment":212},{"nctId":"NCT07088250","phase":"NA","title":"Statins for Treatment of Primary Intracerebral Hemorrhage","status":"RECRUITING","sponsor":"The Second Hospital of Anhui Medical University","startDate":"2023-05-06","conditions":"Cerebrovascular Disorders, Intracranial Hemorrhages, Intracranial Hemorrhage","enrollment":264},{"nctId":"NCT06930092","phase":"NA","title":"RestoratIon of Myocardial Function by PeRcutaneous cOronary interVEntion in Patients With Ischemic CardioMyoPathy","status":"RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2025-07-01","conditions":"Ischemic Cardiomyopathy","enrollment":158},{"nctId":"NCT06564909","phase":"PHASE2","title":"Effect of L-Carnitine on Biomarkers of Myocardial Reperfusion Injury in Patients With STEMI","status":"RECRUITING","sponsor":"Ain Shams University","startDate":"2025-06-01","conditions":"Reperfusion Injury, Myocardial, Myocardial Infarction","enrollment":76},{"nctId":"NCT05514938","phase":"PHASE2","title":"Polypill in Acute Coronary Syndrome","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2022-11-30","conditions":"Acute Coronary Syndrome, Lipid Disorder, Coronary Artery Disease","enrollment":140},{"nctId":"NCT06825676","phase":"NA","title":"Guideline-diRected MAnagement for Chronic Kidney Disease: EValuation of an Education Progamme in a National Cluster Randomized Controlled Trial","status":"NOT_YET_RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2025-03","conditions":"Renal Insufficiency, Chronic, Cardiovascular Diseases (CVD)","enrollment":1800},{"nctId":"NCT05845424","phase":"PHASE4","title":"High-intensity Statin and Ezetimibe Therapy for Asymptomatic Patients With Positive Coronary Calcium","status":"RECRUITING","sponsor":"Samsung Medical Center","startDate":"2023-07-03","conditions":"Coronary Artery Calcification, Metabolic Syndrome, Dyslipidemias","enrollment":6000},{"nctId":"NCT05419583","phase":"NA","title":"Targeting Investigation and Treatment in Patients With Type 2 Myocardial Infarction","status":"COMPLETED","sponsor":"University of Edinburgh","startDate":"2022-11-14","conditions":"Myocardial Infarction Type 2","enrollment":60},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT06469528","phase":"PHASE3","title":"ESCALATion of Medical Therapy Following Multimodality Plaque Evaluation in High-risk Chronic Coronary Syndromes","status":"NOT_YET_RECRUITING","sponsor":"King's College Hospital NHS Trust","startDate":"2024-06-24","conditions":"Coronary Artery Disease","enrollment":50},{"nctId":"NCT04606459","phase":"NA","title":"COSIMA: COronary SInus Reducer for the Treatment of Refractory Microvascular Angina","status":"RECRUITING","sponsor":"Johannes Gutenberg University Mainz","startDate":"2021-04-01","conditions":"Coronary Microvascular Disease, Refractory Angina","enrollment":144},{"nctId":"NCT03255044","phase":"PHASE4","title":"Comparison of Lipophilic Versus Hydrophilic Statins on Patients With Heart Failure","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2017-06-15","conditions":"Heart Failure","enrollment":85}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Guideline directed statin therapy","genericName":"Guideline directed statin therapy","companyName":"Samsung Medical Center","companyId":"samsung-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Statins inhibit HMG-CoA reductase to reduce cholesterol synthesis and lower LDL cholesterol levels in the blood. Used for Primary prevention of atherosclerotic cardiovascular disease in high-risk patients, Secondary prevention of cardiovascular events in patients with established coronary artery disease or other atherosclerotic disease, Hyperlipidemia and dyslipidemia management.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}